X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Methycobal (methylcobalamin) is the active form of vitamin B12. It is indicated for the treatment of peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency.
Lead Product(s): Methylcobalamin
Therapeutic Area: Neurology Product Name: Methycobal
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2024
Details:
Mecobalamin (generic name, development code: E0302) is approved and marketed as Methycobal®, a 500 µg injection of mecobalamin indicated for the treatment of peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency.
Lead Product(s): Methylcobalamin
Therapeutic Area: Neurology Product Name: E0302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
An analysis of Study 761 suggested that ultrahigh-dose E0302 (methylcobalamin) prolonged survival period and suppressed progression in ALS patients who commenced treatment within 12 months of ALS onset.
Lead Product(s): Methylcobalamin
Therapeutic Area: Neurology Product Name: E0302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
